Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).